Screener
Maze Therapeutics MAZE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 34,940 | 28,108 | 69,088 | 55,688 |
| General and administrative | 13,095 | 8,366 | 25,500 | 16,187 |
| Total operating expenses | 48,035 | 36,474 | 94,588 | 71,875 |
| Loss from operations | (48,035) | (36,474) | (74,588) | (71,875) |
| Other income (expense): | ||||
| Interest and other income, net | 4,239 | 2,795 | 7,450 | 5,410 |
| Interest expense | (931) | — | (1,797) | — |
| Total other income, net | 3,308 | 2,795 | 5,653 | 5,410 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's operating income?
- Maze Therapeutics (MAZE) reported operating income of -$48.04M in Q2 2026.
- How has Maze Therapeutics's operating income changed year-over-year?
- Maze Therapeutics's operating income decreased by 31.7% year-over-year, from -$36.47M to -$48.04M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Maze Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude